

Special Issue

Precision Medicine in Myeloma: Current, Past and Future

Message from the Guest Editors

Multiple myeloma (MM) is a plasma cell dyscrasia arising from malignant transformation of plasma cells. It is usually preceded by monoclonal gammopathy of uncertain significance (MGUS). Despite the availability of numerous newer therapies in the last two decades, this biologically heterogeneous disease remains largely incurable with variable disease course and susceptibility to treatment. To date, there is no therapy targeting specific patient groups based on molecular characteristics and biomarkers, and drug-refractory relapses invariably occur. In recent years, advances in technology and treatment have enabled the development of novel strategies for predicting survival and progression risk in myeloma. These approaches have the potential to transform the management of these diseases by enabling the implementation of precision medicine strategies tailored to individual patient needs. We encourage submission of both original research articles and topical reviews. All submitted articles will undergo peer review.

Guest Editors

Dr. Chung Hoow Kok

Centre for Cancer Biology, Adelaide University, Adelaide, SA 5000, Australia

Dr. Cindy H. S. Lee

Royal Adelaide Hospital, Adelaide, SA 5000, Australia

Deadline for manuscript submissions

closed (28 April 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/173183

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)